MSB_logo_notag (001).jpg
Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease
November 27, 2015 06:00 ET | Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...
Mesoblast Chairman's Address to 2015 Annual General Meeting
October 22, 2015 02:00 ET | Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting. This has been another exciting and productive year in the history of our...
Full Product Approval In Japan Received By Mesoblast Licensee
September 18, 2015 01:23 ET | Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...